Matt Kaeberlein discusses the exciting developments in the field of aging interventions, highlighting the potential to slow down and even reverse declines in health and longevity. He explores various interventions that can be initiated in middle or late age in mice, including the significant impact of rapamycin. Peter Attia adds insights on the appropriate age to start interventions and the challenges of genetic manipulation.
